ArticleBMC microbiology2022
Distribution of serotypes and antibiotic resistance of invasive Pseudomonas aeruginosa in a multi-country collection.
Article in BMC microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 59 citations in OpenAlex.
- XAB06, a glyco-humanized broad-spectrum anti-Antimicrobial agents and chemotherapy · 2026Article
- Pseudomonas aeruginosa ST4936 with extensive antibacterial drug resistance and virulence determinants from ureteral stent biofilms: whole-genome insights.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Emerging pathogens in urinary tract infections: virulence and phenotypic characterization ofmSphere · 2026Article
- Intracellular barriers and receptor masking limit success of abioRxiv : the preprint server for biology · 2026Article
- Synergistic Bactericidal Effects of R- and F-Type Pyocin Cocktails Against ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- WGS reveals high-risk clones of Pseudomonas aeruginosa harbouring extensive antimicrobial and predicted anti-phage defense systems recovered from diabetic foot ulcer patients in Egypt.BMC microbiology · 2026Article
- Genomic characteristics and risk factor analysis of carbapenem-non-susceptible Pseudomonas aeruginosa causing bacteremia in a tertiary hospital (2014-2023).BMC microbiology · 2026Article
- Current and future options for the treatment of serious infections due to carbapenem-resistantClinical microbiology reviews · 2025Review
- Prevalence and effective treatment of drug-resistant Pseudomonas aeruginosa biofilm using flavonoid naringin.Bioprocess and biosystems engineering · 2025Article
- Virulence and Resistance ofMicroorganisms · 2025Article
- Role of R5 pyocin in the predominance of high-risk Pseudomonas aeruginosa isolates.Microbiological research · 2025Article
- STING-adjuvanted outer membrane vesicle nanoparticle vaccine against Pseudomonas aeruginosa.JCI insight · 2025Article
- NovelmBio · 2025Article
- Occurrence and Genotypic Characterization of Selected Multidrug-resistant ESKAPE-E Pathogens Isolated from Integrated Smallholder Fresh Produce Farms.Journal of food protection · 2025Article
- Molecular characterization of serotype and virulence genes ofJournal of medical microbiology · 2025Article
- Novel broadly reactive monoclonal antibody protects againstInfection and immunity · 2025Article
- Genetic and virulence factors behind the success of high-riskFrontiers in microbiology · 2025Article
- Genomic features and fitness cost of co-existence ofFrontiers in cellular and infection microbiology · 2025Article
- An unnatural amino acid dependent, conditional Pseudomonas vaccine prevents bacterial infection.Nature communications · 2024Article
- Genomic Differences Associated with Resistance and Virulence inMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 15 institutions in 12 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas aeruginosa is an opportunistic pathogen that causes a wide range of acute and chronic infections and is frequently associated with healthcare-associated infections. Because of its ability to rapidly acquire resistance to antibiotics, P. aeruginosa infections are difficult to treat. Alternative strategies, such as a vaccine, are needed to prevent infections. We collected a total of 413 P. aeruginosa isolates from the blood and cerebrospinal fluid of patients from 10 countries located on 4 continents during 2005-2017 and characterized these isolates to inform vaccine development efforts. We determined the diversity and distribution of O antigen and flagellin types and antibiotic susceptibility of the invasive P. aeruginosa. We used an antibody-based agglutination assay and PCR for O antigen typing and PCR for flagellin typing. We determined antibiotic susceptibility using the Kirby-Bauer disk diffusion method.
resultsOf the 413 isolates, 314 (95%) were typed by an antibody-based agglutination assay or PCR (n = 99). Among the 20 serotypes of P. aeruginosa, the most common serotypes were O1, O2, O3, O4, O5, O6, O8, O9, O10 and O11; a vaccine that targets these 10 serotypes would confer protection against more than 80% of invasive P. aeruginosa infections. The most common flagellin type among 386 isolates was FlaB (41%). Resistance to aztreonam (56%) was most common, followed by levofloxacin (42%). We also found that 22% of strains were non-susceptible to meropenem and piperacillin-tazobactam. Ninety-nine (27%) of our collected isolates were resistant to multiple antibiotics. Isolates with FlaA2 flagellin were more commonly multidrug resistant (p = 0.04).
conclusionsVaccines targeting common O antigens and two flagellin antigens, FlaB and FlaA2, would offer an excellent strategy to prevent P. aeruginosa invasive infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.